Thrombophilia References

References

  1. National Blood Clot Alliance, “https://www.stoptheclot.org/antithrombin-deficiency

  2. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency

  3. Heit, J.A.,et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.

  4. Centers for Disease Control and Prevention, “Leading Causes of Death,” https://www.cdc.gov/nchs/fastats/leading-causes-of-death

  5. Centers for Disease Control and Prevention, “Venous Thromboembolism (Blood Clots): Data and Statistics,” https://www.cdc.gov/ncbddd/dvt/data.html

  6. National Blood Clot Alliance, “Hospitalization: A Major Risk Factor for Dangerous Blood Clots,” https://www.stoptheclot.org/spreadtheword/wp-content/uploads/2016/06/Hospitalization-Infographic.pdf

  7. Heit, J.A., et. al., “The Epidemiology of Venous Thromboembolism,” J of Thromb Thrombolysis, 2016; 41: 3-14.

  8. Bates, S., et. al., “Guidance for the treatment and prevention of obstetric-associated venous thromboembolism,” J Thromb Thrombolysis (2016) 41:92–128

  9. Schick, P., Medscape, “Hereditary and Acquired Hypercoagulability Workup: Laboratory Studies,” May 26,2016. https://emedicine.medscape.com/article/211039-workup

10. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.


11. National Blood Clot Alliance, “https://www.stoptheclot.org/antithrombin-deficiency

12. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.


13. Ibid.

14. Ibid.

15. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK, MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. doi: 10.15585/mmwr.rr6503a1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.

16. Ornstein, D., “Cardiology Update: Factor V Leiden,” Circulation. 2003;107:e94-e97.


17. Ibid.

18. Patnaik MM, Moll S. Haemophilia. 2008;14(6):1229-1239.; Wells PS, Blajchman MA,
Henderson P, et al. Am J Hematol. 1994;45:321-324.

19. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Hereditary Antithrombin Deficiency,” https://ghr.nlm.nih.gov/condition/hereditary-antithrombin-deficiency

20. The Clinical Adviser, “Antithrombin Deficiency,” http://www.clinicaladvisor.com/labmed/antithrombin-deficiency/article/614356/

21. Varga, E., et.al., “Prothrombin 20210 Mutation (Factor II Mutation),” Circulation 2004;110;e15-e18. http://circ.ahajournals.org/content/110/3/e15

22. Ibid.

23. Miletich, J., et.al., Absence of Thrombosis in Subjects with Heterozygous Protein C Deficiency, New England Journal of Medicine, 1987;317:991-996

24. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein C Deficiency,” https://ghr.nlm.nih.gov/condition/protein-c-deficiency#resources

25. U.S. National Library of Medicine: Genetics Home Reference, “Your Guide to Understanding Genetic Conditions: Protein S Deficiency,” https://ghr.nlm.nih.gov/condition/protein-s-deficiency#genes

26. Mandava, P., et. al., “Drugs and Diseases: Homocystinuria/Homocysteinemia,” Medscape, https://emedicine.medscape.com/article/1952251-overview#a3

27. Piazza, G., “Thrombophilia and Hypercoagulability,” Circulation, 2014;130:e9-e10.


28. Connors, J., “Thrombophilia Testing and Venous Thrombosis,” N Engl J Med 2017;377:1177-87.


29. Ansell, J., “Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum,” J Thromb Thrombolysis, 2016:41:1-2.

30. Vedantham, S., “Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism,” J Thromb Thrombolysis (2016) 41:72.

31. Burnett, A., et. al., “Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment,” J Thromb Thrombolysis, (2016) 41:1.

32. Ibid.

33. Ibid.

34. B Myers, R Neal, O Myers, M Ruparelia, Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning, Obstet Med. 2016 Mar; 9(1): 40–42. Published online 2015 Dec 24. doi: 10.1177/1753495X15621814

Current News

NBCA Names Corewell Health the Inaugural NBCA VTE Center of Excellence

The NBCA VTE Centers of Excellence designation recognizes excellence in clinical outcomes, patient education, and post-hospitalization patient care for blood…

Blood Clot Awareness Month Just Got Bigger and Brighter!

We are absolutely thrilled to reveal that the National Blood Clot Alliance has a public service announcement on the seven-story-high…